register

News & Trends - Pharmaceuticals

UCB secures registration of rheumatology drug

Health Industry Hub | May 8, 2024 |

Pharma News: UCB Australia has secured Therapeutic Goods Administration (TGA) approval of its therapy for psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). Bimzelx (bimekizumab) was reviewed during the March PBAC for Pharmaceutical Benefits Scheme (PBS) reimbursement.

Bimzelx is a monoclonal antibody that selectively inhibits IL-17A and IL-17F, two key cytokines that play a hand in the inflammatory process.

Professor Stephen Hall, rheumatologist at the Cabrini Medical Centre, said “Having been involved in the bimekizumab clinical trial program, I am looking forward to the opportunity to prescribe bimekizumab in the real world for this expanded group of patients.

“Adults living with psoriatic arthritis and axial spondyloarthritis often experience a range of severe symptoms affecting their quality of life, including swollen and stiff joints, chronic pain and irreversible structural damage. The TGA registration of Bimzelx potentially provides a valuable new treatment option for patients.”

review published in January 2024 assessed Bimzelx’s performance against other available psoriasis and PsA treatments.

“The results demonstrated the favourable relative efficacy and safety of bimekizumab 160 mg Q4W vs all approved treatments for PsA. Bimekizumab ranked high in terms of efficacy on joint, skin and minimal disease activity (MDA) outcomes in both b/tsDMARD-naïve and TNFi-experienced patient populations, and showed comparable safety to other treatments.”

Francesca Bianco, Immunology PVU Head at UCB Australia, said “Our ambition at UCB is to transform the lives of people living with severe diseases. We are pleased to bring a new treatment option to healthcare professionals and people living with psoriatic arthritis and axial spondyloarthritis in Australia.”

This approval follows the TGA registration of Bimzelx in March 2022 for treating moderate to severe plaque psoriasis in adult patients eligible for systemic therapy or phototherapy.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


Human Resources

The return-to-office debate: Where are we in the pendulum's swing?

The return-to-office debate: Where are we in the pendulum’s swing?

Health Industry Hub | May 24, 2024 |

People & Culture: The evolution of hybrid and flexible workplaces has yielded mixed results across the healthcare sector, with some […]

More


News & Trends - MedTech & Diagnostics

Cardinal Health launches local facility for reprocessing of single-use medical devices

Cardinal Health launches local facility for reprocessing of single-use medical devices

Health Industry Hub | May 24, 2024 |

MedTech & Diagnostics News: Cardinal Health is set to launch a cutting-edge facility in Australia dedicated to the reprocessing of […]

More


Medical

New ophthalmic centre to partner on pharma and medtech clinical trials

New ophthalmic centre to partner on pharma and medtech clinical trials

Health Industry Hub | May 24, 2024 |

Medical: The Victorian Deputy Premier and Minister for Medical Research, the Hon Ben Carroll, has launched a cutting-edge ophthalmic clinical […]

More


News & Trends - Pharmaceuticals

Private sector, government and academia gather to tackle barriers in vaccine value chain

Private sector, government and academia gather to tackle barriers in vaccine value chain

Health Industry Hub | May 24, 2024 |

Pharma News: An ‘invite only’ vaccine thought leadership event, aimed at addressing gaps in Australia’s vaccine ecosystem and maximising the […]

More


This content is copyright protected. Please subscribe to gain access.